Quantitative Imaging in Cancer Clinical Trials

Quantitative Imaging in Cancer Clinical Trials.

As anticancer therapies designed to target specific molecular pathways have been developed, it has become critical to develop methods to assess the response induced by such agents. Although traditional, anatomic CT, and MRI examinations are useful in many settings, increasing evidence suggests that these methods cannot answer the fundamental biologic and physiologic questions essential for asse...

Quantitative Imaging in Clinical Trials

Imaging in clinical trials

Drug development continues to face challenges to successfully progress the most promising drug candidates through the stages of clinical trials. Given the increasing cost to develop a drug, methods are required to characterise early drug efficacy and safety. Imaging techniques are increasingly used in oncological clinical trials to provide evidence for decision making. With the application of c...

Imaging in Clinical Trials

Introduction We are experiencing a time of great growth in knowledge about human disease. However, translation of the knowledge into clinical practice has not kept pace. Clinical trials are an important part of the drug development process. The cost of conducting clinical trials has become greater because: 1) regulations on how the trial must be conducted have become more complex; 2) proposed t...

Clinical trials in cancer.

Randomized controlled trials (RCTs) in cancer are expensive, slow, and often preclude other exploratory investigations that might be valuable. Two types of RCTs should not be conducted. When the results of exploratory studies are so dramatically different from all prior experience, RCTs should be done to improve upon the new finding but not to allocate some patients to inferior control arms to ...